One-Two Punch of Romosozumab, Denosumab Improved BMD and Reduced Fractures
AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 years of denosumab in women with osteoporosis, an analysis of the FRAME studies suggested. Treatment with romosozumab first was associated with a 16.8% increase […]